Publication:
GranuLab: Strategies for growth

Simple item page
cris.lastimport.scopus2024-12-06T16:20:52Z
dc.FundingDetailsMinistry of Education, Science and Technology,�MEST
dc.FundingDetailsGranuMaS was the product of a research funded by the Malaysian Ministry of Science and Technology that began in 2000. The research was conducted by a group of researchers from three Malaysian public universities (UKM, USM and IIUM) and one government research institute (Nuclear Malaysia). This research team was led by an officer from SIRIM, a Malaysian government research agency. The objective of this research was to find halal alternative (lawful and good for use by Muslim patients) to existing allograft (bone grafts made from tissues of human donors) and xenograft (bone grafts made from animal tissue). GranuMaS, which was made from religiously permissible substances, was considered qualified as a halal product. In 2005, with the transfer of GranuMaS technology to GranuLab, the product was ready for commercialization. One year later, the company was acquired by Sindora, a large diversified public-listed
dc.contributor.affiliationsFaculty of Economics and Muamalat
dc.contributor.affiliationsUniversiti Sains Islam Malaysia (USIM)
dc.contributor.affiliationsUniversiti Putra Malaysia (UPM)
dc.contributor.affiliationsUniversiti Teknologi MARA (UiTM)
dc.contributor.affiliationsUniversiti Kebangsaan Malaysia (UKM)
dc.contributor.authorAdham K.A.en_US
dc.contributor.authorSaid M.F.en_US
dc.contributor.authorSarkam S.F.en_US
dc.contributor.authorSa'Adah Muhamad N.en_US
dc.date.accessioned2024-05-28T08:47:28Z
dc.date.available2024-05-28T08:47:28Z
dc.date.issued2015
dc.description.abstractGranuLab SDN. Bhd. (GranuLab) was in the business of manufacturing patented synthetic bone graft substitute made from limestones and pure chemicals called GranuMaS. The bone graft substitute industry in Malaysia was a growing market with many large multinational players. In December 2010, the company began selling GranuMaS to several Malaysian hospitals. It had also completed the construction of its new production facility in Shah Alam, about 30 km from Malaysia's capital city of Kuala Lumpur. With the facility's pending operation in January 2011, the company had to find ways to leverage its high-volume production capacity. GranuLab's approval for the CE Mark certification for GranuMaS' exporting as well as the ISO certification to operate as an OEM contract manufacturing provider were still pending. Therefore, it was unable to export GranuMaS to Europe and other international markets, forcing the company to restrict its sales within Malaysia. Each day, the need to bring in revenue from sales of GranuMaS was mounting for Mr. Romli Ishak, the Managing Director of GranuLab particularly with the manufacturing facility due to begin its operation soon. Mr. Romli and his management team began to ponder on the appropriate strategies to adopt in order to achieve the company's objective of high profitability. This teaching case is designed to stimulate discussion regarding strategic posturing of a young medical device company with aspirations for high growth. � 2015 World Scientific Publishing Company.
dc.description.natureFinalen_US
dc.identifier.doi10.1142/S0218927515500169
dc.identifier.epage471
dc.identifier.issn2189275
dc.identifier.issue2
dc.identifier.scopus2-s2.0-84962182232
dc.identifier.spage443
dc.identifier.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-84962182232&doi=10.1142%2fS0218927515500169&partnerID=40&md5=b2c64c6124472651458b2186303976b7
dc.identifier.urihttps://oarep.usim.edu.my/handle/123456789/9461
dc.identifier.volume19
dc.languageEnglish
dc.language.isoen_USen_US
dc.publisherWorld Scientific Publishing Co. Pte Ltden_US
dc.relation.ispartofAsian Case Research Journal
dc.sourceScopus
dc.titleGranuLab: Strategies for growthen_US
dc.typeArticleen_US
dspace.entity.typePublication

Files

Collections

Scopus